Patents by Inventor Françoise Lejeune

Françoise Lejeune has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20110311563
    Abstract: The current invention relates to the diagnosis and treatment of diseases resulting from infections by Mycobacterium avium subsp. paratuberculosis. In particular the invention relates to the use of an antigen selected among (a) a synthetic peptide 5P having the following formula: DPhe-NMeVal-Ile-Phe-Ala-OMe (SEQ ID NO: 1); (b) a lipopeptide L5P consisting of the synthetic peptide a) wherein the N-terminal phenylalanine residue is N-acylated with an eicosanoic acid acyl chain; (c) a variant of peptide a) or lipopeptide b) able to react with anti-Mycobacterium paratuberculosis antibodies; for in vitro detection or quantification of specific anti-Mycobacterium paratuberculosis antibodies in a biological sample.
    Type: Application
    Filed: October 24, 2008
    Publication date: December 22, 2011
    Inventors: Jean-Marc Reyrat, Sylvie Bay, Franck Biet, Francoise Lejeune, Gilles Bariteau, Denise Hirsch
  • Patent number: 6743818
    Abstract: A compound selected from those of formula (I): wherein: n represents integer from 0 to 6, R1 represents a group selected from hydrogen, hydroxy, cyano, alkoxy, alkoxycarbonyl, carboxy, optionally substituted aminocarbonyl, and NR4R5 wherein R4, and R5 are as defined in the description, R2 represents a group selected from hydrogen, alkyl, hydroxymethyl, and —U—V—W wherein T, U, V, and W are as defined in the description, and R3 represents a group selected from hydrogen, linear or branched (C1-C6)alkyl, aryl, and, heteroaryl, its isomers, and also addition salts thereof with a pharmaceutically-acceptable acid or base, and medicinal products containing the same are useful in the treatment of CNS disorders.
    Type: Grant
    Filed: July 12, 2002
    Date of Patent: June 1, 2004
    Assignee: Les Laboratoires Servier
    Inventors: Jean-Louis Peglion, Bertrand Goument, Mark Millan, Françoise Lejeune, Didier Cussac
  • Publication number: 20030032812
    Abstract: A compound selected from those of formula (I): 1
    Type: Application
    Filed: July 12, 2002
    Publication date: February 13, 2003
    Inventors: Jean-Louis Peglion, Bertrand Goument, Mark Millan, Francoise Lejeune, Didier Cussac
  • Patent number: 6452015
    Abstract: A compound selected from those of formula (I): wherein: n represents integer from 0 to 6, R1 represents a group selected from hydrogen, hydroxy, cyano, alkoxy, alkoxycarbonyl, carboxy, optionally substituted aminocarbonyl, and NR4R5 wherein R4, and R5 are as defined in the description, R2 represents a group selected from hydrogen, alkyl, hydroxymethyl,  and -U-V-W wherein T, U, V, and W are as defined in the description, and R3 represents a group selected from hydrogen, linear or branched (C1-C6)alkyl, aryl, and, heteroaryl, its isomers, and also addition salts thereof with a pharmaceutically-acceptable acid or base, and medicinal products containing the same are useful in the treatment of CNS disorders.
    Type: Grant
    Filed: April 12, 2001
    Date of Patent: September 17, 2002
    Assignee: Les Laboratoires Servier
    Inventors: Jean-Louis Peglion, Bertrand Goument, Mark Millan, Françoise Lejeune, Didier Cussac
  • Patent number: 6420413
    Abstract: A compound selected from those of formula (I): wherein: denotes single bond or double bond, n is integer from 1 to 6 inclusive, R1, and R2 represent a group selected from hydrogen, linear or branched (C1-C6)-alkyl, aryl, arylalkyl, cycloalkyl, cycloalkylalkyl, alkenyl, alkynyl, heterocycloalkyl, heterocycloalkylalkyl, heteroaryl, and heteroarylalkyl, X represents a group selected from —CH═CH—, oxygen, S(O)m wherein m is integer from 0 to 2 inclusive, and NR3 wherein R3 represents a group as defined in the description, Y represents CH or CH2 depending on whether denotes single bond or double bond, or may have the additional meaning of oxygen when X represents oxygen, T represents monocyclic or polycyclic (C3-C10)cycloalkyl optionally containing within the ring system oxygen, selenium, S(O)p, NR3, or SiR4R5 wherein p, R3, R4, and R5 are as defined in the description, its isomers and addition salts thereof with a pharmaceutically-accep
    Type: Grant
    Filed: April 12, 2001
    Date of Patent: July 16, 2002
    Assignee: Les Laboratories Servier
    Inventors: Jean-Louis Peglion, Aimée Dessinges, Bertrand Goument, Mark Millan, Françoise Lejeune, Mauricette Brocco
  • Patent number: 6365605
    Abstract: Compounds of formula (I): wherein: m is 0 to 3 inclusive, n is 0 to 3 and 2≦m+n≦3, p is 1 to 6 inclusive, X represents cyano or —CO—NR4R5, R4 and R5 being selected from hydrogen, linear or branched (C1-C6)-alkyl, (C3-C7)-cycloalkyl, and aryl, R1 and R2 each independently represent hydrogen or linear or branched (C1-C6)-alkyl, R3 represents hydrogen, optionally substituted phenyl, naphthyl or heteroaryl, or aryloxy or arylthio, or aryl or heteroaryl substituted by A′-Cy, A′ and Cy being as defined in the description, and medicinal products containing the same which are useful as D3 receptor ligands.
    Type: Grant
    Filed: January 10, 2000
    Date of Patent: April 2, 2002
    Assignee: Les Laboratoires Servier
    Inventors: Gilbert Lavielle, Thierry Dubuffet, Patrick Hautefaye, Françoise Lejeune, Mark Millan
  • Publication number: 20020019380
    Abstract: A compound selected from those of formula (I): 1
    Type: Application
    Filed: April 12, 2001
    Publication date: February 14, 2002
    Inventors: Jean-Louis Peglion, Aimee Dessinges, Bertrand Goument, Mark Millan, Francoise Lejeune, Mauricette Brocco
  • Patent number: 6326377
    Abstract: Compounds of formula (I): wherein: m is 0 to 3 inclusive, n is 0 to 3 and 2≦m+n≦3, p is 1 to 6 inclusive, X represents cyano or —CO—NR4R5, R4 and R5 being selected from hydrogen, linear or branched (C1-C6)-alkyl, (C3-C7)-cycloalkyl,and aryl, R1 and R2 each independently represent hydrogen or linear or branched (C1-C6)-alkyl, R3 represents hydrogen, optionally substituted phenyl, naphthyl or heteroaryl, or aryloxy or arylthio, or aryl or heteroaryl substituted by A′—Cy, A′ and Cy being as defined in the description, and medicinal products containing the same which are useful as D3 receptor ligands.
    Type: Grant
    Filed: January 10, 2000
    Date of Patent: December 4, 2001
    Assignee: Adir et Compagnie
    Inventors: Gilbert Lavielle, Thierry Dubuffet, Patrick Hautefaye, Françoise Lejeune, Mark Millan
  • Publication number: 20010044426
    Abstract: A compound selected from those of formula (I): 1
    Type: Application
    Filed: April 12, 2001
    Publication date: November 22, 2001
    Inventors: Jean-Louis Peglion, Bertrand Goument, Mark Millan, Francoise Lejeune, Didier Cussac
  • Patent number: 6025356
    Abstract: New compounds of formula: ##STR1## wherein: A represents alkyl, alkenyl, alkynyl, cycloalkylalkyl or aralkyl, andE represents: ##STR2## in racemic form or in the form of optical isomers, and the addition salts thereof with pharmaceutically acceptable acids.Those compounds may be used as medicaments.
    Type: Grant
    Filed: August 31, 1998
    Date of Patent: February 15, 2000
    Assignee: Adir et Compagnie
    Inventors: Jean-Louis Peglion, Jean-Christophe Harmange, Mark Millan, Francoise Lejeune